Trial · NCT07897019
Efficacy and Safety of Almonertinib Combined With Recombinant Human Endostatin in the Treatment of Stage IIIB-IV Non-small Cell Lung Cancer
NCT07897019, Terminated, Three Gorges Hospital of Chongqing University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Almonertinib Combined With Recombinant Human Endostatin in the Treatment of Stage IIIB-IV Non-small Cell Lung Cancer. Trials, record NCT07897019. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07897019
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Almonertinib Combined With Recombinant Human Endostatin in the Treatment of Stage IIIB-IV Non-small Cell Lung Cancer
- NCT number
- NCT07897019
- Status
- Terminated
- Enrollment
- 1 participants, actual
- Lead sponsor
- Three Gorges Hospital of Chongqing University
- Conditions
- Non-Small Cell Lung Cancer
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | progression-free survival (PFS) | 3 months | Refers to the time from the start of a randomized clinical trial to tumor progression (in any aspect) or death from any cause. |
| Secondary | objective response rate | 3 months | Refers to the proportion of patients whose tumors shrink or stabilize for a certain period of time, including cases of complete remission (CR), partial remission (PR) and stable disease (SD) |
| Secondary | Adverse events | 3 months | Adverse medical events that occur after a clinical trial participant receives a drug |
| Secondary | Global Health Status/Quality of Life Measured by EORTC QLQ-C30 | 3 months | Assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The global health status/quality of life (GHS/QoL) scale score ranges from 0 to 100; higher scores indicate better quality of life. |
| Secondary | Depressive Symptoms Measured by Patient Health Questionnaire-9 (PHQ-9) | 3 months | Assessed using the Patient Health Questionnaire-9 (PHQ-9). The total score ranges from 0 to 27; higher scores indicate more severe depressive symptoms. |
| Secondary | Anxiety Symptoms Measured by HADS Anxiety Subscale (HADS-A) | 3 months | Assessed using the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). The subscale score ranges from 0 to 21; higher scores indicate more severe anxiety symptoms. |
| Secondary | Depressive Symptoms Measured by HADS Depression Subscale (HADS-D) | 3 months | Assessed using the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D). The subscale score ranges from 0 to 21; higher scores indicate more severe depressive symptoms. |
| Secondary | Duration of Remission | 3 months | refers to the time from the first assessment of CR or PR to the first assessment of PD or death from any cause. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07897019
GET https://conductscience.org/api/trials/v1/NCT07897019/registered